Skip to main content

Table 3 Prevalence of ermF and ermB macrolide resistance genes over time

From: Prevalence and abundance of selected genes conferring macrolide resistance genes in COPD patients during maintenance treatment with azithromycin

  ermF
% (pos/all samples)
ermB
% (pos/all samples)
Prevalence Placebo Azithromycin P value Placebo Azithromycin P value
Baseline 44,4 (16/36) 59,1 (26/44) 0.261 86,1 (31/36) 97,7 (43/44) 0.085
M6 43,3 (13/30) 67,6 (23/34) 0.050 80,0 (24/30) 97,1 (33/34) 0.029*
M12 48,1 (13/27) 68,8 (22/32) 0.109 74,1 (20/27) 100,0 (32/32) 0.002*
  1. *Prevalence of ermB is statistically significant in the Azithromycin group at M6 and M12 compared to the Placebo group (Chi-square, Pearson corrected)